14.
HEMATOPOIESIS DURING "LIVING HIGH-TRAINING LOW" IN ELITE RUNNERS. Julien
V BRUGNIAUX
1
, Paul ROBACH
2
, Laurent SCHMITT
3
, Françoise LASNE
4
, Stéphane
MOUTEREAU
5
, Marie-Claude CHORVOT6, Philippe SAAS6, Jérémy CORNOLO
1
, Niels V
OLSEN7, Jean-Paul RICHALET
1
. EA
23
6
3
, ARPE, Université Paris
13
, Bobigny, France
1
, ENSA,
Chamonix, France
2
, CNSN, ID Jacobeys, Prémanon, France
3
, LNDD, Châtenay-Malabry,
France
4
, Laboratoire de biochimie, Hôpital Henri-Mondor, Créteil, France
5
, INSERM/UPRES
EA, EFS, Besançon, France6, Department of Pharmacology, The Panum Institute, University of
Copenhagen, Copenhagen, Denmark7.
This study tried to elucidate which stage of red cell production is influenced by 18 days of
"living high-training low" exposure to hypoxia. Twelve male athletes performed an 18-day of
living hightraining low training session at 1100m, by sleeping either in ambient air (CON, n=6)
or in hypoxic rooms (HYP, n=5, with 3 nights at 2500m and 15 nights at 3000m, mean daily
exposure = 14h/24h). The measurements were performed at 1100m, before (PRE), during
(H3000, i.e. after the 2nd night at 3000m), and 1 (POST1) and 15 days (POST2). Hemoglobin
and hematocrit were not modified in both groups. Reticulocyte count (RETIC) did not change at
POST1 for both groups but decreased at POST2 vs. PRE (-17.9% for HYP, -25% for CON). Red
cell volume (RCV) did not significantly increase from PRE to POST1 (+9.2%) for HYP, although
4 subjects presented an increase in RCV. Ferritin was significantly decreased at H3000 for HYP
(-12.3%) and at POST1 for CON (-20.6%) vs. PRE. Soluble transferrin receptor increased from
PRE to H3000 and POST1 for the two groups (11% and 20% for HYP, 7.5% and 13.5% for
CON, respectively, P<0.05) and remained higher at POST2 for HYP (10.9%, P<0.05 vs. PRE).
Erythropoietin was lower in CON than in HYP, both at H3000 and POST2 (P<0.05). Burst
Forming Unit-erythroid (BFU-e) increased in both groups at POST1 vs. PRE. Values for CON
were significantly higher than for HYP. BFU-e and RETIC were correlated (r=0.82) for HYP but
no relation was found between mature red cell and BFU-e or RETIC. These results suggest that
this exposure to hypoxia may not be sufficient to change RCV for all subjects. This study was
supported by grants from the International Olympic Committee and the French Ministry of
Sports.
15.
GROWTH SUPPRESSION OF HUMAN UMBILICAL CORD ENDOTHELIUM BY
RHODIOLA EXTRACT. Ga Bu
1
, Yang Feng
2
, Sui You-Lan
1
, Chen Rong-Hua
2
, Yan Hui
3
,
Zhang Jing-Ling
4
. The Second Peoples hospital of Tibet, Lhasa, China,
1
, Institute of Basic
Medical Sciences, CAMS and PUMC, Beijing, China
2
, The First Peoples Hospital of Tibet,
Lhasa, China,
3
, Shangdong Qianfuoshan Hospital, Jinan, China
4
.
Purpose: To observe the effect of rhodiola extract on cell growth of human umbilical cord
endothelium, and to explore its possible role in preventing or improving high altitude diseases.
Methods: 25g rhodiola was soaked in 160ml saline for 24h. The saline with rhodiola extract was
filtered and the concentration is equal to 156 mg/ml. The IC50 (50% cell survival concentration)
of rhodiola for human umbilical cord endothelium is 1.4mg/ml. Endothelium cells in treatment
group was cultured in culture medium with final concentration of rhodiola extraction at 1.56,
2.34, 3.12,and 3.9 mg/ml. Control group had no rhodiola extract added. Cell cycle was
determined by FCM (flow cytometry). Results: The total number of cells in treatment group was
less than that of the control group and they had more G1 phase cells and less S phase cells than
that of the control group as well. The result indicates that the addition of rhodiola extract
inhibited the cell growth by suppressing cells to reach G1 phase. No apoptosis was observed in
either group. Conclusion: Rhodiola can suppress the growth of human endothelium by inhibiting
cell proliferation, which provides the possible implication of preventing the narrowing of the
arterial wall and pulmonary hypertension in patients with high altitude diseases.
